Trial · NCT02933450
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
NCT02933450, Phase 4, Completed, Baylor College of Medicine; results first posted 2019-05-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE). Trials, record NCT02933450. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02933450
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
- NCT number
- NCT02933450
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 43 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Kidney Failure, Chronic
- Interventions
- Patiromer 25.2 g
- First posted
- 2016-10-14
- Last updated
- 2019-05-09
- Results first posted
- 2019-05-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of Patiromer in Reducing Serum Potassium | 6 hours | serial serum potassium levels will be graphed and compared between the 2 groups |
| Secondary | Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting. | 6 hours | adverse events will be recorded and compared between the 2 groups |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of Patiromer in Reducing Serum Potassium | 6 hours | mEq/L | MEAN | |
| SECONDARY | Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting. | 6 hours | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of Patiromer in Reducing Serum Potassium | Patiromer | 1 hr | 6.17 | 95% Confidence Interval 5.94 to 6.46 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Standard of Care | 1 hr | 6.6 | 95% Confidence Interval 6.33 to 6.86 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Patiromer | 2 hr | 5.9 | 95% Confidence Interval 5.67 to 6.2 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Standard of Care | 2 hr | 6.47 | 95% Confidence Interval 6.21 to 6.73 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Patiromer | 4 hr | 5.73 | 95% Confidence Interval 5.5 to 6.02 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Standard of Care | 4 hr | 6.04 | 95% Confidence Interval 5.77 to 6.30 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Patiromer | 6 hr | 5.81 | 95% Confidence Interval 5.51 to 6.16 | mEq/L |
| Efficacy of Patiromer in Reducing Serum Potassium | Standard of Care | 6 hr | 6.27 | 95% Confidence Interval 5.97 to 6.58 | mEq/L |
| Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting. | Patiromer | Total | 4 | Participants | |
| Tolerability of High Dose Patiromer in ESRD Patients on Hemodialysis in the Acute Setting. | Standard of Care | Total | 5 | Participants |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Patiromer | 20 | |
| Overall Study | STARTED | Standard of Care | 23 | |
| Overall Study | COMPLETED | Patiromer | 15 | |
| Overall Study | COMPLETED | Standard of Care | 15 | |
| Overall Study | NOT COMPLETED | Patiromer | 5 | |
| Overall Study | NOT COMPLETED | Standard of Care | 8 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | GI Side Effects | Gastrointestinal disorders | Patiromer | 1 | 15 | 1 |
| other | GI Side Effects | Gastrointestinal disorders | Standard of Care | 2 | 15 | 2 |
| other | Hypoglycemia | General disorders | Patiromer | 3 | 15 | 3 |
| other | Hypoglycemia | General disorders | Standard of Care | 3 | 15 | 3 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Patiromer | 0 | 15 |
| Total, all-cause mortality | Standard of Care | 0 | 15 |
| Total, other adverse events | Patiromer | 4 | 15 |
| Total, other adverse events | Standard of Care | 5 | 15 |
| Total, serious adverse events | Patiromer | 0 | 15 |
| Total, serious adverse events | Standard of Care | 0 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Patiromer vs Standard of Care: deaths from any cause | Trial comparisons |
| Patiromer vs Standard of Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02933450
GET https://conductscience.org/api/trials/v1/NCT02933450/registered